Shots:
- The P-III JUNIPERA study assesses the efficacy and safety of secukinumab (75 /150 mg) vs PBO in 86 children and adolescents aged 2-17yrs. with a confirmed diagnosis of JPsA or ERA (subtype of JIA)
- The study met its 1EPs i.e delayed time to flare and demonstrates efficacy with more patients achieving and maintains the JIA ACR 30 and JIA ACR 70 responses @12 to 104 wks., favorable safety profile with no new safety signals were identified with 2yrs. treatment
- The regulatory submissions in the EU and the US are expected in the coming wks. The therapy has received EU and US approval as a 1L systemic treatment for pediatric psoriasis
Click here to read full press release/ article | Ref: Novartis | Image: Reuters
The post Novartis Presents Two-Year Data of Cosentyx in P-III JUNIPERA Study for JPsA and ERA at EULAR 2021 first appeared on PharmaShots.
